<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00022438</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068818</org_study_id>
    <secondary_id>NCI-01-C-0193</secondary_id>
    <secondary_id>NCI-5369</secondary_id>
    <nct_id>NCT00022438</nct_id>
    <nct_alias>NCT00017849</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment</brief_title>
  <official_title>Immunization of HLA-0201 Positive Patients With Metastatic Melanoma Using a Peptide From Tyrosinase-related Protein 2 (TRP-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.&#xD;
      Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining&#xD;
      vaccine therapy with interleukin-2 may be an effective treatment for metastatic melanoma.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of vaccine therapy plus&#xD;
      interleukin-2 to that of vaccine therapy alone in treating patients who have metastatic&#xD;
      melanoma that has not responded to previous treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the clinical responses in patients with HLA-A0201-positive refractory&#xD;
           metastatic melanoma treated with tyrosinase-related protein-2:180-188 peptide vaccine&#xD;
           alone.&#xD;
&#xD;
        -  Determine the clinical response rate of patients who have an immediate need to receive&#xD;
           interleukin-2 (IL-2) in addition to this vaccine.&#xD;
&#xD;
        -  Compare the immunologic response, in terms of changes in T-cell precursors before and&#xD;
           after treatment, in patients treated with this vaccine with or without IL-2.&#xD;
&#xD;
        -  Compare the toxicity profile of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label study.&#xD;
&#xD;
      Patients who need immediate interleukin-2 (IL-2) receive tyrosinase-related protein-2&#xD;
      (TRP-2):180-188 peptide vaccine emulsified with Montanide ISA-51 on day 1 and high-dose IL-2&#xD;
      IV over 15 minutes once every 8 hours on days 2-5. Treatment repeats every 3 weeks for up to&#xD;
      4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients who do not need immediate IL-2 are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive TRP-2:180-188 peptide vaccine emulsified with Montanide ISA-51&#xD;
           subcutaneously (SC) on day 1. Treatment repeats every 3 weeks for up to 4 courses in the&#xD;
           absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive TRP-2:180-188 peptide vaccine emulsified with Montanide ISA-51&#xD;
           SC once weekly on weeks 1-4. Treatment repeats every 7 weeks for up to 4 courses in the&#xD;
           absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients who have a complete response (CR) receive 1 additional course after achieving CR.&#xD;
      Patients who have progressive disease while receiving vaccine alone may cross over to receive&#xD;
      peptide vaccine with IL-2 for at least 2 courses.&#xD;
&#xD;
      Patients are followed at 3 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 83 patients (19-33 who need immediate interleukin-2 (IL-2);&#xD;
      15-25 per treatment arm who do not need immediate IL-2) will be accrued for this study within&#xD;
      1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant tyrosinase-related protein-2</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of metastatic melanoma&#xD;
&#xD;
               -  Refractory to standard therapy&#xD;
&#xD;
               -  No resectable locoregional disease&#xD;
&#xD;
          -  HLA-A0201 positive&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Previously resected brain metastases, brain metastases stable after prior&#xD;
             radiosurgery, or brain metastases less than 1 cm and without edema allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 90,000/mm^3&#xD;
&#xD;
          -  No coagulation disorders&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL (3.0 mg/dL for patients with Gilbert's syndrome)&#xD;
&#xD;
          -  AST/ALT less than 3 times normal&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No major medical illness of the cardiovascular system&#xD;
&#xD;
          -  No cardiac ischemia*&#xD;
&#xD;
          -  No myocardial infarction*&#xD;
&#xD;
          -  No cardiac arrhythmias* NOTE: * For interleukin-2 (IL-2) administration&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No major medical illness of the respiratory system&#xD;
&#xD;
          -  No obstructive or restrictive pulmonary disease (for IL-2 administration)&#xD;
&#xD;
        Immunologic:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No primary or secondary immunodeficiency&#xD;
&#xD;
          -  No known immunodeficiency disease&#xD;
&#xD;
          -  No autoimmune disease&#xD;
&#xD;
          -  No active systemic infections&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior biologic therapy for melanoma&#xD;
&#xD;
          -  No prior immunization to tyrosinase-related protein-2 antigen&#xD;
&#xD;
          -  No other concurrent biologic therapy for melanoma&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy for melanoma and recovered&#xD;
&#xD;
          -  No concurrent chemotherapy for melanoma&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior endocrine therapy for melanoma&#xD;
&#xD;
          -  No concurrent systemic steroid therapy&#xD;
&#xD;
          -  No concurrent endocrine therapy for melanoma&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy for melanoma and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy for melanoma&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent therapy for melanoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2004</verification_date>
  <study_first_submitted>August 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

